Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study.
Renova Therapeutics has announced the selection of Worldwide Clinical Trials as its CRO for an upcoming gene therapy study. Worldwide Clinical Trials will support the Phase III study of RT-100 AC6 gene transfer for the treatment of patients with reduced ejection fraction heart failure.
Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.